185 related articles for article (PubMed ID: 25086585)
21. Account for Clinical Heterogeneity in Assessment of Catheter-based Renal Denervation among Resistant Hypertension Patients: Subgroup Meta-analysis.
Chen XH; Kim S; Zeng XX; Chen ZB; Cui TL; Hu ZX; Li Y; Fu P
Chin Med J (Engl); 2017 Jul; 130(13):1586-1594. PubMed ID: 28639575
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of resistant hypertension and eligibility for catheter-based renal denervation in hypertensive outpatients.
Hayek SS; Abdou MH; Demoss BD; Legaspi JM; Veledar E; Deka A; Krishnan SK; Wilmot KA; Patel AD; Kumar VR; Devireddy CM
Am J Hypertens; 2013 Dec; 26(12):1452-8. PubMed ID: 23934709
[TBL] [Abstract][Full Text] [Related]
23. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
[TBL] [Abstract][Full Text] [Related]
24. Renal denervation in moderate treatment-resistant hypertension.
Ott C; Mahfoud F; Schmid A; Ditting T; Sobotka PA; Veelken R; Spies A; Ukena C; Laufs U; Uder M; Böhm M; Schmieder RE
J Am Coll Cardiol; 2013 Nov; 62(20):1880-6. PubMed ID: 23850901
[TBL] [Abstract][Full Text] [Related]
25. Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension.
Fadl Elmula FE; Jin Y; Yang WY; Thijs L; Lu YC; Larstorp AC; Persu A; Sapoval M; Rosa J; Widimský P; Jacobs L; Renkin J; Petrák O; Chatellier G; Shimada K; Widimský J; Kario K; Azizi M; Kjeldsen SE; Staessen JA;
Blood Press; 2015; 24(5):263-74. PubMed ID: 26194721
[TBL] [Abstract][Full Text] [Related]
26. Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom.
Thompson M; Bartko-Winters S; Bernard L; Fenton A; Hutchison C; Di Iorio B
J Med Econ; 2013; 16(6):744-55. PubMed ID: 23550810
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
[TBL] [Abstract][Full Text] [Related]
28. Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands.
Stevanović J; O'Prinsen AC; Verheggen BG; Schuiling-Veninga N; Postma MJ; Pechlivanoglou P
Clin Ther; 2014 Mar; 36(3):368-84.e5. PubMed ID: 24534654
[TBL] [Abstract][Full Text] [Related]
29. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries.
Ara R; Pandor A; Tumur I; Paisley S; Duenas A; Williams R; Wilkinson A; Durrington P; Chilcott J
Clin Ther; 2008 Aug; 30(8):1508-23. PubMed ID: 18803993
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study.
McInnes G; Burke TA; Carides G
J Hum Hypertens; 2006 Jan; 20(1):51-8. PubMed ID: 16357874
[TBL] [Abstract][Full Text] [Related]
31. Improvement of albuminuria after renal denervation.
Ott C; Mahfoud F; Schmid A; Ditting T; Veelken R; Ewen S; Ukena C; Uder M; Böhm M; Schmieder RE
Int J Cardiol; 2014 May; 173(2):311-5. PubMed ID: 24681017
[TBL] [Abstract][Full Text] [Related]
32. Renal denervation--hypes and hopes.
Lewek J; Kaczmarek K; Pokushalov E; Romanov A; Cygankiewicz I; Ptaszynski P
Cardiovasc Ther; 2015 Jun; 33(3):141-4. PubMed ID: 25786785
[TBL] [Abstract][Full Text] [Related]
33. Rationale and design of the Investigator-Steered Project on Intravascular Renal Denervation for Management of Drug-Resistant Hypertension (INSPiRED) trial.
Jin Y; Jacobs L; Baelen M; Thijs L; Renkin J; Hammer F; Kefer J; Petit T; Verhamme P; Janssens S; Sinnaeve P; Lengelé JP; Persu A; Staessen JA;
Blood Press; 2014 Jun; 23(3):138-46. PubMed ID: 24742341
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of self-management of blood pressure in hypertensive patients over 70 years with suboptimal control and established cardiovascular disease or additional cardiovascular risk diseases (TASMIN-SR).
Penaloza-Ramos MC; Jowett S; Mant J; Schwartz C; Bray EP; Sayeed Haque M; Richard Hobbs FD; Little P; Bryan S; Williams B; McManus RJ
Eur J Prev Cardiol; 2016 Jun; 23(9):902-12. PubMed ID: 26603745
[TBL] [Abstract][Full Text] [Related]
35. The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK.
Batty AJ; Hansen RN; Bloudek LM; Varon SF; Hayward EJ; Pennington BW; Lipton RB; Sullivan SD
J Med Econ; 2013 Jul; 16(7):877-87. PubMed ID: 23647483
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma.
Hoyle M; Green C; Thompson-Coon J; Liu Z; Welch K; Moxham T; Stein K
Value Health; 2010; 13(1):55-60. PubMed ID: 19804431
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.
Locker GY; Mansel R; Cella D; Dobrez D; Sorensen S; Gandhi SK;
Breast Cancer Res Treat; 2007 Dec; 106(2):229-38. PubMed ID: 17245540
[TBL] [Abstract][Full Text] [Related]
38. Cost-utility analysis of physician-pharmacist collaborative intervention for treating hypertension compared with usual care.
Kulchaitanaroaj P; Brooks JM; Chaiyakunapruk N; Goedken AM; Chrischilles EA; Carter BL
J Hypertens; 2017 Jan; 35(1):178-187. PubMed ID: 27684354
[TBL] [Abstract][Full Text] [Related]
39. Renal denervation for resistant hypertension: yes.
Boschetti E; Alrashdi Y; Schillaci G
Intern Emerg Med; 2016 Jun; 11(4):491-3. PubMed ID: 26970989
[TBL] [Abstract][Full Text] [Related]
40. Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.
Wielage RC; Bansal M; Andrews JS; Klein RW; Happich M
Appl Health Econ Health Policy; 2013 Jun; 11(3):219-36. PubMed ID: 23616247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
